Allogene Therapeutics announced that CEO David Chang will step down at the end of June after eight years in the role. The company said Chang is handing over leadership to Zachary Roberts, who moves from chief medical officer and head of R&D into the CEO position. The transition arrives amid shifting internal priorities for an off-the-shelf CAR-T franchise and highlights how leadership changes often coincide with program readouts and pipeline reshaping in cell therapy. In the same news cycle, the Allogene item also appeared alongside an update that Agios’ next-generation PK activator failed a key blood cancer study.